ARS PharmaceuticalsSPRY
SPRY
About: ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Employees: 160
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
106% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 18
40% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 43
9% more funds holding
Funds holding: 150 [Q3] → 164 (+14) [Q4]
7.26% more ownership
Funds ownership: 66.08% [Q3] → 73.33% (+7.26%) [Q4]
19% less capital invested
Capital invested by funds: $928M [Q3] → $752M (-$176M) [Q4]
26% less call options, than puts
Call options by funds: $2.68M | Put options by funds: $3.65M
67% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 1 (-2) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$30
115%
upside
Avg. target
$30
115%
upside
High target
$30
115%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank Louise Chen 27% 1-year accuracy 32 / 118 met price target | 115%upside $30 | Sector Outperform Initiated | 7 Mar 2025 |
Financial journalist opinion
Positive
Seeking Alpha
15 hours ago
ARS Pharmaceuticals Has A Blockbuster Candidate
ARS Pharmaceuticals has a recently launched needle-free epinephrine product for allergic reactions, neffy, and strong cash reserves. The company targets a ~$3B+ U.S. market, geographic expansion and intends to also address acute flares in chronic spontaneous urticaria. Financial projections include $500M peak U.S. sales, $500M outside the U.S., and $150M for chronic spontaneous urticaria, with profitability expected by 2027.
Positive
Seeking Alpha
1 month ago
ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await
ARS Pharmaceuticals, Inc.'s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy's competitive edge lies in its innovative intranasal delivery, targeting a $3 billion initial addressable market in the U.S. with potential growth prospects. Despite neffy's potential, risks include competition, pricing pressures, and single-asset dependency, leading to a "Hold" recommendation due to commercial uncertainties.
Neutral
Seeking Alpha
1 month ago
ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President and CEO Eric Karas - Chief Commercial Office Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Alexa Deemer - Cantor Fitzgerald Louise Chen - Scotia Bank Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Julian Harrison - BTIG Operator Good day, and welcome to ARS Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.
Positive
Investors Business Daily
1 month ago
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.
Shares of ARS Pharmaceuticals bounded higher Thursday after the company reported an unexpected fourth-quarter metrics. The post ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move.
Positive
Zacks Investment Research
1 month ago
ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.07 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
$7.3 million in total neffy ® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024
Neutral
GlobeNewsWire
1 month ago
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children
Neutral
GlobeNewsWire
1 month ago
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, March 20, 2025, at 8:30 a.m.
Neutral
GlobeNewsWire
2 months ago
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions, bringing the total number of formulary platforms covering neffy to 30
Neutral
GlobeNewsWire
2 months ago
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
Oral presentation on an efficacy study conducted in Japanese patients comparing anaphylaxis symptoms during oral food challenge with neffy as the initial treatment compared to site historical data on intramuscular auto-injectors, antihistamines and inhalers; patients receiving neffy had lower symptom scores within 10 minutes, supporting neffy as a needle-free option for management of anaphylaxis neffy was shown to be in the safe and efficacious range for children four years or older who weigh more than 15 kilograms Findings in Chinese studies confirms U.S. data and bracketed pharmacokinetic (PK) and pharmacodynamic (PD) profiles, demonstrate neffy's comparable efficacy and safety under various conditions including self-administration, allergic rhinitis, infectious rhinitis, in allergy challenges and with repeat dosing, compared with intermuscular injection SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that nine presentations will be featured at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting, February 28 to March 3, in San Diego, California. The oral presentation and posters will feature data from a wide range of studies, including pharmacokinetics and pharmacodynamics of intranasal epinephrine under normal and various conditions, physiological responses between adults and children who are administered epinephrine, and the pre-treatment journey of patients with allergic conditions.
Charts implemented using Lightweight Charts™